Cassava Sciences, Inc. Stock News

In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer's drug, simufilam.

Cassava Sciences (SAVA), the Austin-based biotech firm specializing in neurodegenerative diseases, suffered a major blow on Monday when its stock plunged 85%. The sharp drop came after the company announced that its Phase 3 clinical trial for simufilam, an experimental Alzheimer's treatment, failed to meet its primary endpoints.

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. The post Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops appeared first on Investor's Business Daily.

Cassava Sciences (SAVA) shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug—aimed at treating Alzheimer's disease (AD)—failed to show a “significant reduction in cognitive or functional decline” during the Phase 3 trial of the treatment.

The biotech says it will discontinue a second trial but will still offer full analyses of the data.

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study

AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs